SEARCH:   Advanced

Blood, 1 April 2004, Vol. 103, No. 7, pp. 2799-2801. Prepublished online as a Blood First Edition Paper on October 23, 2003; DOI 10.1182/blood-2003-06-1840. This Article Full Text (PDF) All Versions of this Article: 2003-06-1840v1 103/7/2799    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Rogers, A. Articles by Albitar, M. Search for Related Content PubMed PubMed Citation Articles by Rogers, A. Articles by Albitar, M. Social Bookmarking                   What's this? Submitted June 10, 2003 Accepted October 5, 2003 Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia Anna Rogers, Youngson Joe, Amanda Dey, Iman Jilani, Francis Giles, Elihu Estey, Emil Freireich, Michael Keating, Hagop Kantarjian, and Maher Albitar* Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA Department of Hematopathology, Quest Diagnostics Inc., Nichols Institute, San Juan Capistrano, CA, USA * Corresponding author; email: maher.x.albitar{at}questdiagnostics.com. Using loss of heterozygosity (LOH) and X-chromosome inactivation, we compared peripheral blood (PB) plasma with bone marrow (BM) cells in detecting genomic abnormalities in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). We detected LOH in the PB plasma of all 45 patients who had cytogenetically documented chromosomal abnormalities (5q-, -7, +8, -17 or -20). BM cells from the same patients showed LOH in 89% of MDS and 70% of AML patients. Post-therapy samples from 16 of these patients demonstrated complete concordance between LOH and cytogenetics in detecting residual disease in 15 samples. Four of the 16 samples showed LOH in plasma with normal BM morphology. Using X-chromosome inactivation, clonality was detectable in 19 of 26 (73%) BM samples, while all PB plasma samples showed clonality. This data supports the conclusion that PB plasma is enriched by tumor-specific DNA and can replace BM cells for studying genomic abnormalities. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. Hohaus, M. Giachelia, G. Massini, G. Mansueto, B. Vannata, V. Bozzoli, M. Criscuolo, F. D'Alo, M. Martini, L. M. Larocca, et al. Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas Ann. Onc., August 1, 2009; 20(8): 1408 - 1413. [Abstract] [Full Text] [PDF] W. Ma, H. Kantarjian, X. Zhang, W. Sun, A. M. Buller, I. Jilani, J. G. Schwartz, F. Giles, and M. Albitar Higher detection rate of JAK2 mutation using plasma Blood, April 1, 2008; 111(7): 3906 - 3907. [Full Text] [PDF] W. Ma, R. Tseng, M. Gorre, I. Jilani, M. Keating, H. Kantarjian, J. Cortes, S. O'Brien, F. Giles, and M. Albitar Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia Haematologica, February 1, 2007; 92(2): 170 - 175. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020